Dr. Apolo on Immunotherapy Combinations With Cabozantinib in Genitourinary Tumors

Andrea B. Apolo, MD
Published: Tuesday, Jun 13, 2017



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses immunotherapy combinations with cabozantinib (Cometriq) in genitourinary tumors.

In a phase I study, cabozantinib plus nivolumab (Opdivo), as well as cabozantinib/nivolumab plus ipilimumab (Yervoy) was evaluated in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors.

Apolo reports that the overall response rate for the entire cohort is 37%, while the bladder cancer cohort is 44%.
 


Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses immunotherapy combinations with cabozantinib (Cometriq) in genitourinary tumors.

In a phase I study, cabozantinib plus nivolumab (Opdivo), as well as cabozantinib/nivolumab plus ipilimumab (Yervoy) was evaluated in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors.

Apolo reports that the overall response rate for the entire cohort is 37%, while the bladder cancer cohort is 44%.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x